Irinotecan Viatris

Irinotecan Hydrochloride Trihydrate, the active ingredient in Irinotecan Viatris, is a Topoisomerase I inhibitor presented as an injectable solution for intravenous use. It is employed in the treatment of colorectal cancer, metastatic colorectal cancer and other solid tumours. GNH USA supplies Irinotecan Viatris as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Irinotecan Viatris is a topoisomerase I inhibitor used in oncology for several solid‑tumour indications.

Colorectal cancer: used as part of combination chemotherapy to control tumour growth. Metastatic colorectal cancer: administered to improve disease control in advanced disease. Other solid tumours: incorporated into regimens for various solid malignancies where topoisomerase I inhibition is indicated.

Irinotecan may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Diarrhoea: often delayed and may be severe. - Nausea and vomiting. - Neutropenia: reduced white blood cell count. - Alopecia: hair loss. - Fatigue and weakness. - Abdominal cramping.

Serious or Rare Side Effects: - Febrile neutropenia: infection with fever. - Severe colitis or intestinal perforation. - Anaphylactic or severe allergic reactions. - Hepatotoxicity: elevated liver enzymes. - Severe electrolyte disturbances. - Rare cases of pulmonary toxicity.

Prior to initiating therapy, several safety considerations should be observed.

Monitor blood counts: perform regular complete blood counts to detect neutropenia. Assess liver function: obtain baseline and periodic liver enzyme tests. Maintain hydration: ensure adequate fluid intake to mitigate diarrhoea risk. Avoid strong CYP3A4 inhibitors: concurrent use may increase irinotecan exposure. Pregnancy safety: unknown; avoid use in pregnant women unless benefits outweigh risks. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Irinotecan can interact with other medicines, altering its efficacy or toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase systemic exposure and toxicity. - Concurrent myelosuppressive agents: heightened risk of severe bone‑marrow suppression.

Moderate Interactions (Monitor Closely): - Carboplatin or other platinum compounds: additive myelosuppression. - Warfarin: potential increase in bleeding risk. - UGT1A1 inhibitors (e.g., atazanavir): may raise SN‑38 levels and toxicity.